Garmin (Venu / Fenix / Forerunner) vs Evie Ring (and EvieMED) in 2026

Garmin (Venu / Fenix / Forerunner)

Garmin (the Venu 3 as the biometric-primary anchor at about $449; the Fenix 8 and Forerunner 965 are more athletics-primary and pricier) is the lightest-cleared-portfolio entry in the biometric cohort. Its sensors (Elevate optical heart rate, Pulse Ox/SpO2, ECG on select models, skin temperature) drive Body Battery, Training Load and Training Readiness, advanced sleep and a sleep coach, all-day stress and HRV Status, and a Morning Report.

The verified-vs-claimed distinction matters here: only the ECG is FDA-cleared (a 510(k) in 2023, on select models); Body Battery, recovery, and the broader readiness metrics are wellness-grade, and Pulse Ox is not FDA-cleared. Garmin is purchase-only (founded 1989); the optional Garmin Connect+ AI subscription ($6.99/month, March 2025) does not gate any existing features. DEPLOY cap-flags any reading of Garmin's wellness metrics as cleared diagnostics; only the ECG carries a clearance.

Evie Ring (and EvieMED)

Movano Health's Evie Ring is a women's-health-focused smart ring (menstrual-cycle tracking, sleep, energy, heart rate, SpO2, and mood and goal trends; general-wellness, not a diagnostic) and the lifecycle-state-paused archetype of DEPLOY's biometric ring sub-cohort. The verified-vs-claimed distinction is critical: Evie Ring sales are PAUSED, not discontinued.

Following Movano Health's Corvex reverse merger (closed March 19, 2026), an AI-infrastructure pivot, and a 1-for-10 reverse split, the company paused Evie Ring sales while a divestiture of its EvieMED clinical line is pending. EvieMED (the B2B/clinical variant) is an FDA 510(k)-cleared pulse oximeter and heart-rate device (December 2, 2024) for clinical trials, remote patient monitoring, and payors and pharma.

DEPLOY records the consumer Evie Ring at paused availability with no current retail price. Aggregators routinely flatten this as 'Movano discontinued the Evie Ring'; the accurate state is sales-paused amid a corporate pivot, with the EvieMED divestiture pending (an intention where not yet closed). Movano Health trades as NASDAQ: MOVE (CEO John Mastrototaro).